BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Key Stats

• Today's Range: $5.46 to $6.01
• 50-Day Range: $4.95 to $6.29
• 52-Week Range: $5.46 to $7.70
• Volume: 13,179 shs
• Average Volume: 6,517 shs
• Market Capitalization: $97.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

BHST Stock Analysis - Frequently Asked Questions

How have BHST shares performed this year?

BioHarvest Sciences' stock was trading at $6.18 at the beginning of 2025. Since then, BHST shares have decreased by 3.7% and is now trading at $5.95.
View the best growth stocks for 2025 here.

Who are BioHarvest Sciences' major shareholders?

Top institutional shareholders of BioHarvest Sciences include TD Waterhouse Canada Inc. (0.07%).

How do I buy shares of BioHarvest Sciences?

Shares of BHST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 2/22/2025
• Next Earnings (Estimated): 4/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CUSIP: N/A
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +118.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.2490)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,560,000.00
• Net Margins: -76.65%
• Pretax Margin: -76.65%
• Return on Equity: N/A
• Return on Assets: -85.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.80
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $12.67 million
• Price / Sales: 7.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.08) per share
• Price / Book: -5.51

Miscellaneous

• Outstanding Shares: 16,420,000
• Free Float: N/A
• Market Cap: $97.70 million
• Optionable: N/A
• Beta: 2.65